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Serological screening of recombinant cDNA expression libraries has been widely used for the identiﬁcation of tumour antigens
in various cancer types. Identiﬁcation of tumour antigens in ovarian cancer may facilitate the development of vaccine-based
therapies and of disease biomarkers. The purpose of our investigation is to identify tumour antigens in ovarian cancer by using
the serological analysis of recombinant cDNA expression libraries method. A recombinant ovarian carcinoma cDNA
expression library was screened with ascites ﬂuid, pooled from ﬁve ovarian cancer patients. Twelve tumour antigens encoded
by known genes were isolated, including ribosomal protein S18, heat shock protein 90, JK-recombination signal binding
protein, ribonucleoprotein H1, RAN binding protein 7, TG-interacting factor, eukaryotic translation initiation factor p40
subunit, human amyloid precursor protein-binding protein 1, ribosomal protein L8, CDC23, IQ motif containing GTPase
activating protein 1, and ribosomal protein L3. Heat shock protein 90 was chosen for further investigation. The prevalence of
hsp90 autoantibodies in ovarian cancer was determined with immunoassay. Sera from 22 normal females, 32 from ovarian
cancer (22 stage III/IV, 10 stage I/II), 37 colorectal cancer, 13 breast cancer, 10 lung cancer, 20 benign gynaecologic diseases,
and 10 benign breast lesions were screened. Seven (32%) stage III/IV ovarian cancer, 1 (10%) stage I/II ovarian cancer, 1 (3%)
colorectal cancer, 1 (8%) breast cancer, and 1 (5%) benign gynaecologic disease sera were found to contain hsp90
autoantibodies. These data support the view that hsp90 autoantibodies are frequently found in late stage ovarian cancer.
Hsp90 may, therefore, represent a novel biomarker for ovarian cancer and a candidate ovarian cancer vaccine target.
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Aberrantly expressed or mutated cellular and cell surface proteins
in human cancer can break self-tolerance and trigger immune
responses. These proteins are known as tumour antigens (Boon
and van der Bruggen, 1996). One example of tumour antigens is
p53 (Angelopoulou et al, 1994; Soussi, 2000). To facilitate the iden-
tiﬁcation of tumour antigens in cancer, serological analysis of
recombinant cDNA expression libraries (SEREX) technology was
developed (Sahin et al, 1995). In this technique, sera from cancer
patients are used to screen recombinant cDNA expression libraries,
constructed from tumour tissues. Tumour antigens in the libraries
are isolated due to their immunoreactivities to the autoantibodies
in the sera. So far, more than 1000 candidate tumour antigens in
many types of cancer have been identiﬁed (Chen, 2000). Tumour
antigens identiﬁed by SEREX or similar techniques have two major
clinical applications. First, tumour antigens induce production of
autoantibodies, found in the circulation. These autoantibodies
could represent novel biomarkers for cancer diagnosis, prognosis,
monitoring, and predicting response to chemotherapy. A number
of tumour antigen-derived autoantibodies have already been widely
used as biomarkers in various types of cancer, such as p53, c-erbB-
2/HER2/neu and MUC1/CA15.3 (Angelopoulou et al, 1996, 1997;
Angelopoulou and Diamandis, 1997; Molina et al, 1998; Duffy,
1999). Second, these tumour antigens can be used as targets for
immunotherapy of cancer. The identiﬁcation of tumour antigens
with SEREX is based on the presence of IgG autoantibodies, the
formation of which relies on CD4+ T lymphocytes (helper T cells).
The identiﬁed tumour antigens, then, conﬁrm presence of a reper-
toire of CD4+ cells which recognize such antigens. CD4+ T
lymphocytes are known to play pivotal roles in anti-tumour
responses (Frasca et al, 1998; Pardoll and Topalian, 1998). Thus,
SEREX-deﬁned tumour antigens could be used as therapeutic
cancer vaccines to provoke antitumour immune responses.
Ovarian cancer is the most lethal gynecologic malignancy. Its
poor survival is due to late diagnosis and ineffective treatments.
When ovarian cancer is diagnosed, more than 75% of patients have
stage III/IV disease, which has a ﬁve-year survival rate of less than
25%. Current management of ovarian cancer includes cytoreduc-
tive surgery followed by platinum-based chemotherapy. However,
only a proportion of patients beneﬁts from chemotherapy. So
far, there is no biomarker available to help predict which patients
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www.bjcancer.comwill respond to chemotherapy in ovarian cancer. There is an urgent
need for such biomarkers as well as of new therapeutic regimens.
Cancer vaccines, aiming at clearing residual tumour after surgery,
are now under investigation in ovarian cancer (Butts, 1999). There-
fore, tumour antigens identiﬁed by SEREX could provide candidate
targets for ovarian cancer vaccines. Here, we attempt to identify
tumour antigens in ovarian cancer with SEREX. Our previous work
with SEREX and ovarian cancer has led to the identiﬁcation of a
novel gene which is down-regulated in testicular cancer and has
an isoform solely expressed in the central nervous system (Luo et
al, 2001). We now report identiﬁcation of 12 new candidate ovar-
ian cancer antigens one of which, heat shock protein 90 (hsp90),
was studied in detail and found to be immunogenic in 30% of
advanced stage ovarian cancer.
MATERIALS AND METHODS
Immunoscreening of an ovarian carcinoma cDNA
expression library with ascites ﬂuid from ovarian cancer
patients
The Uni-ZAP
TM premade ovarian carcinoma cDNA expression
library was purchased from Stratagene, La Jolla, CA, USA. Ovarian
cancer ascites ﬂuids were pooled from ﬁve different primary ovar-
ian cancer patients. The cDNA library was plated on NZY agar
plates at a density of 500 clones/15 cm plate. The plates were incu-
bated at 428C for 4 h to allow plaques to develop. Nitrocellulose
ﬁlters soaked with isopropyl b-D-thiogalactopyranoside (IPTG)
were then laid on top of the plaques and incubated at 378C for
4 h to transfer the plaques onto the membranes. Subsequently,
the ﬁlters were blocked with 5% non-fat dry milk/PBS-T (80 mM
sodium orthophosphate, 20 mM sodium dihydrogen orthopho-
sphate, 100 mM sodium chloride, and 0.1% Tween-20) overnight,
at 48C. To screen the library, the ascites were diluted 1:100 in
5% non-fat dry milk/PBS-T. The diluted ascites was ﬁrst incubated
with E. coli phage lysate (from Stratagene) for 2 h at room
temperature to minimize the cross-reaction between the autoanti-
bodies and the bacterial/phage proteins. Nitrocellulose ﬁlters were
then incubated with this preabsorbed ascites for 2 h at room
temperature to identify cellular proteins that react with the autoan-
tibodies in the ascites. Following probing with the ascites, the ﬁlters
were washed with PBS-T for three times and further treated with
alkaline phosphatase-conjugated goat anti-human IgG (Jackson
Immunoresearch Laboratories, West Grove, PA, USA) diluted
2000-fold in 5% non-fat dry milk/PBS-T for 1 h at room tempera-
ture. The ﬁlters were washed again as above and then proceeded to
chemiluminescence detection with a dioxetane-based substrate
(Diagnostic Products Corporation, Los Angeles, CA, USA). The
plaques exhibiting immunoreactivities were excised from the plates
and the phages were converted into pBluescript phagemids by in
vivo excision with Exassist
TM helper phage, following the manufac-
turer’s instructions. The excised phagemids were puriﬁed and
subjected to automated DNA sequencing with M13 forward and
reverse primers. The insert sequences were compared to the known
sequences in the Genbank database with the BLASTN alignment
algorithm (Altschul et al, 1997).
Identiﬁcation of autoantibodies against heat shock protein
90 in various cancer sera with immunoassay
Puriﬁed heat shock protein 90, isolated from HeLa cells, was
purchased from Stressgen, Victoria, BC, Canada. For the immu-
noassay, 100 ml/250 ng well
71 of hsp90 diluted in the coating
buffer (0.1 M ethanolamine in phosphate buffer saline (PBS),
pH 7.2) were ﬁrst directly coated on the 96-well white polystyrene
plate (Greiner Labtechnik, Germany). 100 ml well
71 of 6% bovine
serum albumin (BSA) was also coated as a background control.
After overnight incubation at room temperature, the plate was
washed three times with washing buffer (containing 9 g l
71 NaCl
and 0.5 g l
71 Tween 20 in 10 mmol l
71 Tris buffer, pH 7.40), then
blocked with 200 ml well
71 coating buffer for 1 h. Subsequently, the
plate was washed again as above. 100 ml of human sera, diluted 50-
fold in assay buffer (containing 60 g l
71 BSA, 50 mmol l
71 Tris,
pH 7.80, 2.5% normal mouse serum, 15% normal goat serum, 1%
bovine IgG, and 0.5 g l
71 sodium azide) were then pipetted into
both BSA and hsp90-coated wells, incubated for 1 h and washed
six times. Finally, 100 ml well
71 of alkaline phosphatase-conjugated
goat anti-human IgG, Fc fragment speciﬁc antibody (Jackson
Immunoresearch, West Grove, PA, USA) diluted 5000-fold in assay
buffer was added, incubated for 1 h and washed. The signal was
detected with a time-resolved ﬂuorometric procedure as follows:
100 ml of diﬂunisal phosphate substrate, diluted 10-fold in substrate
buffer (0.1 M Tris, pH 9.1, 0.1 M NaCl and 1 mM MgCl2) were
pipetted into each well and incubated for 10 min. 100 ml of develop-
ing solution (1 M Tris base, 0.4 M NaOH, 2 mM TbCl3, and 3 mM
EDTA) were then added on top. The ﬂuorescence was measured
with a time-resolved ﬂuorometer, the Cyberﬂuor 615 Immunoana-
lyzer (MDS Nordion, Kanata, ON, Canada). The details of this
procedure have been published elsewhere (Christopoulos and
Diamandis, 1992). All serum samples were analysed in duplicate.
Patient sera
The samples used in this study are residual sera of routine testing
from healthy blood donors and patients with various malignancies
and benign diseases. We included sera from 22 normal females and
the following patients: 32 ovarian cancer (22 stage III/IV, 10 stage
I/II), 13 breast cancer, 10 prostate cancer, 10 lung cancer, 20
benign gynecologic diseases, and 10 benign breast lesions. All sera
were stored at 7808C until analysis.
RESULTS
Isolation of tumour antigens by immunoscreening of an
ovarian carcinoma cDNA expression library with ascites
ﬂuid from ovarian cancer patients
A recombinant ovarian carcinoma cDNA library was screened with
ascites pooled from ﬁve ovarian cancer patients. In total, 50000
clones were screened. Twelve clones were found to have immuno-
reactivities. An example of a positive clone is shown in Figure 1.
In order to conﬁrm the identities of these positive clones, they were
isolated and converted to phagemids. The inserts were then
sequenced and compared to the Genbank database with the BLASTN
program. All 12 positive clones are known proteins (Table 1). Most
of these proteins are involved in gene transcription, protein transla-
tion, and mitosis. Heat shock protein 90 was selected for further
evaluation because this protein is commercially available in pure
form, allowing development of an ELISA-type screening assay.
Determination of the prevalence of heat shock protein 90
autoantibodies in ovarian cancer
SEREX technology identiﬁes tumour antigens by screening with
sera which are usually obtained from a small number of patients.
The immunogenicities of the identiﬁed tumour antigens should
therefore be tested in a larger patient population, to determine their
prevalence in various types of cancer. Since the proteins expressed
in the prokaryotic recombinant cDNA expression libraries may
have different conformation or post-translational modiﬁcations
compared to their native human forms, the autoantibodies could
recognize the recombinant proteins, but not the native forms.
Hsp90 was chosen for further evaluation because it was the only
commercially available antigen from the list of Table 1. Puriﬁed
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examine the presence of autoantibodies in the sera from normal
controls, various cancers, and benign diseases. In total, sera from
22 normal female, 32 ovarian cancer (22 stage III/IV, 10 stage I/
II), 37 colorectal cancer, 13 breast cancer, 10 lung cancer, 20 benign
gynecological diseases, and 10 benign breast lesions were screened.
For the 22 normal sera, ﬂuorescence count ratios between hsp90-
coated wells vs BSA-coated wells had a mean of 1.42 and a standard
deviation of 0.28. Thus, the upper limit of the ﬂuorescence ratio
was selected as 2.00, which represents the mean plus two standard
deviations (95% percentile). Sera with ratios 42.00 were deﬁned as
hsp90 autoantibody-positive. With this method, 7 (32%) stage III/
IV ovarian cancer, 1 (10%) stage I/II ovarian cancer, 1 (3%) color-
ectal cancer, 1 (8%) breast cancer, and 1 (5%) benign gynecological
disease sera were found to contain hsp90 autoantibodies (Table 2).
Antibody titers for all sera tested are shown in Figure 2. At the level
of 100% speciﬁcity (ﬂuorescence ratio 42.3), there are still six sera
from late stage ovarian cancer, one serum from early ovarian
cancer, one serum from colorectal cancer, and one serum from a
patient with breast cancer are positive for hsp90 autoantibodies.
Our results indicate that hsp90 autoantibodies are mostly present
in late stage ovarian cancer.
DISCUSSION
In our immunoscreening of the ovarian carcinoma cDNA expres-
sion library, twelve known proteins were identiﬁed as putative
tumour antigens (Table 1). To the best of our knowledge, these
proteins have not been previously reported as ovarian tumour
antigens. However, some of these proteins or their homologues
have already been recognized as tumour antigens by SEREX in
other types of cancer, such as the JK recombination signal binding
protein, eIF2B (a homologue of eIF3) (Gure et al, 2000), and
hsp70 (a homologue of hsp90) (Scanlan et al, 1998). One feature
of many proteins that we identiﬁed is their involvement in gene
transcription, protein translation, and mitosis. Among the 12
proteins of Table 1, 10 belong to these categories. This pattern
is consistent with the SEREX-deﬁned tumour antigens reported
in the literature (Chen, 2000). Although it seems that the immune
responses to these housekeeping proteins may be nonspeciﬁc and
likely related to the high turnover and necrosis associated with
cancer, new experimental evidence indicates that these immuno-
genicities actually result from speciﬁc structural changes or
aberrant expression of these proteins. For example, CDC27, which
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Table 1 Proteins identiﬁed as tumour antigens by immunoscreening of an ovarian carcinoma cDNA expression
library with ovarian cancer ascites.
Clone name Identity Genbank Accession Number Functional signiﬁcance
841 Ribosomal protein S18 X69150 Protein translation
816–3 Heat shock protein 90 kDa M16660 Molecular chaperone
816–4 JK-recombination signal binding protein L07872 Transcription factor
816–5 Ribonucleoprotein H1 L22009 mRNA processing
816–6 RAN binding protein 7 AF098799 Mediate nuclear import
of ribosomal proteins
816–7 TG-interacting factor X89750 Transcription factor
816–8 Eukaryotic translation initiation factor 3
(eIF3), p40 subunit
U54559 Protein translation
816–9 Human amyloid precursor protein-binding
protein 1
U50939 Cleave b amyloid
protein precursor
1210–1 Ribosomal protein L8 NM000973 Protein translation
1210–2 CDC23 (Cell division 23) NM004661 Cell devision
1210–3 IQ motif containing GTPase activating
protein 1 (IQGAP1)
NM003870 Cell–cell adhesion
1210–4 Ribosomal protein L3 NM000967 Protein translation
Figure 1 An example showing a positive clone identiﬁed by immuno-
screening of an ovarian carcinoma cDNA expression library. The black
dot indicated by an arrow is the positive clone.
Table 2 Prevalence of hsp90 autoantibodies in normal controls, various
malignancies, and benign diseases
Number of Number of Positivity
Patient group patients screened positive patients rate (%)
Normal female 22 0 0
Ovarian cancer
Stage III/IV 22 7 32
Stage I/II 10 1 10
Lung cancer 10 0 0
Prostate cancer 20 0 0
Colorectal cancer 37 1 3
Breast cancer 13 1 8
Benign gynaecologic diseases 20 1 5
Benign breast lesion 10 0 0
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gen in melanoma. It has been shown that a mutation within this
gene causes protein structure change, and hence, induction of
immune responses (Wang et al, 1999). In addition, eukaryotic
translation initiation factor 4 (eIF4), which is involved in protein
translation, is a SEREX-deﬁned antigen in lung cancer. It has been
shown that its immunogenicity is due to overexpression (Brass et
al, 1997). We speculate that the proteins identiﬁed here generate
autoimmune reactions through similar mechanisms. It is note-
worthy that eIF3 and CDC23, which are the homologues of eIF4
and CDC27, respectively, were identiﬁed in our screening. Some
of the proteins that we identiﬁed have already been reported to
be overexpressed in various types of cancer, including ribosomal
protein S18 (Chassin et al, 1994), RAN binding protein 7 (Li et
al, 2000), and eIF3, p40 subunit (Nupponen et al, 1999). There-
fore, given the aberrant expression of these proteins in various
malignancies, it is not surprising that they elicit immune
responses.
To examine the prevalence of the hsp90 autoantibodies in ovar-
ian cancer, puriﬁed human hsp90 was used in an ELISA-type
screening assay. In our initial SEREX library screening, we utilized
ascites ﬂuid pooled from ﬁve ovarian cancer patients with late stage
disease. Hsp90 autoantibodies have the highest frequency (32%) in
late stage ovarian cancer, which is consistent with the presence of
hsp90 autoantibodies in the initial ascites pool. Hsp90 autoantibo-
dies were also observed in colorectal cancer (3%) and breast cancer
(8%). It appears that hsp90 is a tumour antigen shared by various
types of cancer. The correlation of hsp90 autoantibodies and late
stage ovarian cancer implies that it may have utilities as a novel
prognostic biomarker for ovarian cancer. In osteosarcoma, hsp90
autoantibody positivity has been found to be associated with
response to chemotherapy, whereas, its absence correlates with
metastasis (Trieb et al, 2000). In contrast, Conroy et al (1998)
reported that the presence of hsp90 autoantibodies indicated
metastasis in breast cancer. What hsp90 autoantibodies could
predict in ovarian cancer awaits further detail investigations to
analyse the relationship of hsp90 autoantibodies and various clin-
icopathological variables.
Hsp90 has been investigated as a cancer vaccine target in animal
models. It has been shown that hsp90 puriﬁed from autologous
tumours has a protective effect in mouse (Graner et al, 2000;
Ullrich et al, 1986). It is now believed that such a protective effect
of hsp90 is mainly due to the tumour-derived antigenic peptides
that bind to it (Ishii et al, 1999; Srivastava et al, 1998; Wells and
Malkovsky, 2000). In our study, since the prokaryotic expression
library and puriﬁed hsp90 from HeLa cells are unlikely to harbour
such antigenic peptides, it seems that the immunoreactivities that
we observed are hsp90 speciﬁc. Our results indicate that hsp90
alone could be used as a cancer vaccine target.
In summary, we show here that many candidate tumour anti-
gens could be identiﬁed in SEREX screening of ovarian cancer.
Our ﬁndings warrant further investigations on these proteins,
aiming to elucidate their immunogenicity in ovarian cancer.
Hsp90 is immunogenic in 32% of late-stage ovarian cancer,
suggesting that it is a potential target for a therapeutic vaccine in
ovarian cancer.
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Figure 2 Distribution of hsp90 autoantibodies in sera from normal
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dotted line indicates the cutoff, 2.0.
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